Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Clinical applications of liquid biopsy in metastatic breast cancer

Michail Ignatiadis • 14 Sep 2024
ESMO 2024
Breast Cancer Capivasertib Copanlisib Elacestrant

Michail Ignatiadis, MD, PhD, Jules Bordet Institute, Brussels, Belgium, describes the use of liquid biopsy and circulating tumor DNA (ctDNA) in managing metastatic breast cancer, particularly for identifying mutations linked to targeted therapies. ctDNA can detect ESR1 mutations for elacestrant, PI3K mutations for copanlisib, and genomic alterations in the PIK3CA/AKT axis for capivasertib. Although these practices are more established in the U.S., the uptake of these assays and treatments is anticipated in Europe soon. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michail Ignatiadis

TREAT ctDNA: early elacestrant intervention for ER+/HER2- breast cancer
2:15
TREAT ctDNA: early elacestrant intervention for ER+/HER2- breast cancer
Michail Ignatiadis • 14 Sep 2024
Challenges in liquid biopsy implementation for metastatic cancer
0:58
Challenges in liquid biopsy implementation for metastatic cancer
Michail Ignatiadis • 14 Sep 2024
Facilitating translational research in clinical trials
3:29
Facilitating translational research in clinical trials
Michail Ignatiadis • 14 Mar 2024
Immune-related adverse events in breast cancer patients taking ICIs
3:03
Immune-related adverse events in breast cancer patients taking ICIs
Michail Ignatiadis • 14 Mar 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals